Say Hello!
Don’t be shy.

0333 323 1843

[email protected]


BioCity Group HQ:
Pennyfoot Street

BiVictriX Therapeutics

BiVictriX Therapeutics

Home > Investment> BiVictriX Therapeutics

Established in 2016, BiVictriX Therapeutics Ltd is a Biotech focused on developing novel, highly-selective, bispecific ADCs to target unmet need in blood cancer. Through the company’s novel “Dual Targeting Approach”, BiVictriX will challenge the conventional ADC therapeutic approach by providing a step change in target selectivity.


BioCity invested in BiVictriX because the explosion of interest in ADCs and the potential for outstanding efficacy with an acceptable profile is possible if you have the right combination of cytotoxics, linkers and highly targeted antibodies.